This trial is testing a new imaging technique to see if it can detect prostate cancer. The technique uses a tracer called 68Ga-FAPi-46 which is taken up by some cancer cells. If successful, this technique could provide additional information about various types of cancer in the future.
- Prostate Cancer
1 Primary · 2 Secondary · Reporting Duration: Up to date of surgery (range 1-60 days)
1 Treatment Group
Basic Science (68Ga-FAPi-46 PET/CT)
1 of 1
30 Total Participants · 1 Treatment Group
Primary Treatment: Gallium Ga 68 FAPi-46 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · Male Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are researchers currently seeking out participants for this clinical experiment?
"Clinicaltrials.gov has verified that this research is recruiting participants, with the posting date of September 9th 2020 and an update on September 23rd 2022." - Anonymous Online Contributor
How many participants are presently joining the trial?
"Yes, clinicaltrials.gov affirms that this experiment is actively recruiting participants. The trial was initially made available on September 9th 2020 and has been edited most recently on the 23rd of September 2022. 30 individuals are required to be enrolled across 1 medical institution." - Anonymous Online Contributor
Has the FDA sanctioned Gallium Ga 68 FAPi-46 for medical use?
"There is only minimal data on Ga 68 FAPi-46's safety and efficacy, so it recieved a score of 1." - Anonymous Online Contributor